CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...
Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...
Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...
Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...
China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...
China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...
China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate...
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...
Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...
China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is preparing to issue 68,292,200...
China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital...
Private equity firm Longreach Group, which specializes in the Asian market, is in the process...
Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...
Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...
The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...
The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin...